Safety and efficacy of laparoscopic cytoreductive surgery in patients with advanced ovarian cancer

Safety and efficacy of laparoscopic cytoreductive surgery and systematic para-aortic lymphadenectomy in patients with advanced ovarian cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1042220022

Enrollment

Registered

2022-05-28

Start date

2022-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer ovarian cancer, laparoscopic

Interventions

laparoscopic staging for advanced ovarian cancer

D010535

laparoscopy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients diagnosed with stage III-IV primary ovarian cancer and treated with preoperative chemotherapy with response to treatment

Exclusion criteria

Exclusion criteria: Patients who have difficulty performing laparoscopic surgery due to invasion of other organs

Design outcomes

Primary

Measure	Time frame
blood loss	—

Secondary

Measure	Time frame
operative time, period of hospitalization, intraoperative and postoperative complications, postoperative QOL, time from surgery to start of chemotherapy, residual status, open conversion rate, overall survival, and disease-free survival	—

Contacts

Public ContactMichiko Kaneda

Mie university hospital

michi_k_1019@yahoo.co.jp+81-59-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026